Papa Alfredo, Scaldaferri Franco, Covino Marcello, Tursi Antonio, Furfaro Federica, Mocci Giammarco, Lopetuso Loris Riccardo, Maconi Giovanni, Bibbò Stefano, Fiorani Marcello, Laterza Lucrezia, Mignini Irene, Napolitano Daniele, Parisio Laura, Pizzoferrato Marco, Privitera Giuseppe, Pugliese Daniela, Schepis Tommaso, Schiavoni Elisa, Settanni Carlo Romano, Vetrone Lorenzo Maria, Armuzzi Alessandro, Danese Silvio, Gasbarrini Antonio
Gastroenterology Department, CEMAD, Center for Diagnosis and Treatment of Digestive Diseases, Fondazione Policlinico Gemelli, IRCCS, 00168 Roma, Italy.
Department of Translational Medicine and Surgery, School of Medicine, Università Cattolica del S. Cuore, 00168 Roma, Italy.
Biomedicines. 2022 Apr 3;10(4):843. doi: 10.3390/biomedicines10040843.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has raised concerns in patients with inflammatory bowel disease (IBD), not only due to consequences of coronavirus disease 2019 itself but also as a possible cause of IBD relapse. The main objective of this study was to assess the role of SARS-CoV-2 in IBD clinical recurrence in a cohort of patients undergoing biological therapy. Second, we evaluated the difference in C-reactive protein (CRP) levels between the start and end of the follow-up period (ΔCRP) and the rate of biological therapy discontinuation. Patients with IBD positive for SARS-CoV-2 infection were compared with non-infected patients. IBD recurrence was defined as the need for intensification of current therapy. We enrolled 95 IBD patients with SARS-CoV-2 infection and 190 non-infected patients. During follow-up, 11 of 95 (11.6%) SARS-CoV-2-infected patients experienced disease recurrence compared to 21 of 190 (11.3%) in the control group (p = 0.894). Forty-six (48.4%) SARS-CoV-2-infected patients discontinued biological therapy versus seven (3.7%) in the control group (p < 0.01). In the multivariate analysis, biological agent discontinuation (p = 0.033) and ΔCRP (p = 0.017), but not SARS-CoV-2 infection (p = 0.298), were associated with IBD recurrence. SARS-CoV-2 infection was not associated with increased IBD recurrence rates in this cohort of patients treated with biological agents.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染引发了炎症性肠病（IBD）患者的担忧，这不仅是由于2019冠状病毒病本身的后果，还可能是IBD复发的一个原因。本研究的主要目的是评估SARS-CoV-2在接受生物治疗的一组患者的IBD临床复发中的作用。其次，我们评估了随访期开始和结束时C反应蛋白（CRP）水平的差异（ΔCRP）以及生物治疗停药率。将SARS-CoV-2感染呈阳性的IBD患者与未感染患者进行比较。IBD复发定义为需要加强当前治疗。我们纳入了95例SARS-CoV-2感染的IBD患者和190例未感染患者。在随访期间，95例（11.6%）SARS-CoV-2感染患者中有11例出现疾病复发，而对照组190例中有21例（11.3%）出现复发（p = 0.894）。46例（48.4%）SARS-CoV-2感染患者停止了生物治疗，而对照组为7例（3.7%）（p < 0.01）。在多变量分析中，生物制剂停药（p = 0.033）和ΔCRP（p = 0.017）与IBD复发相关，而SARS-CoV-2感染（p = 0.298）与IBD复发无关。在这组接受生物制剂治疗的患者中，SARS-CoV-2感染与IBD复发率增加无关。
